Previous 10 | Next 10 |
Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q3 2021 Earnings Call Nov 09, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q3 2021 Earnings Call Transcript
Codex DNA (NASDAQ:DNAY) has acquired Eton Bioscience for approximately $13M in cash. The acquisition is expected to be slightly dilutive to Codex DNA’s earnings per share in 2022, and accretive thereafter. “Together with the Eton team, we will be able to accelerate our BioXp sys...
Codex DNA (NASDAQ:DNAY): Q3 GAAP EPS of -$0.34 misses by $0.05. Revenue of $2.8M (+75.0% Y/Y) misses by $0.13M. For further details see: Codex DNA EPS misses by $0.05, misses on revenue
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the third quarter ended September 30, 2021. “Our passion for innovation and vision to accelerate the crea...
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, announced today that it has agreed to acquire Eton Bioscience, a privately held provider of synthetic biology products and services. “Together...
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the market closes. In conjunction with th...
Codex DNA, Inc. is a new focused synthetic biology company developing lab instruments, reagents, and associated products while providing various other services. Codex DNA's products include the BioXp™ system, a fully automated benchtop instrument for generating synthetic DNA/mR...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...
Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q2 2021 Earnings Call Aug 10, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q2 2021 Earnings Call Transcript
Codex DNA, Inc. (DNAY) Q2 2021 Earnings Conference Call August 10, 2021 05:00 PM ET Company Participants Jennifer McNealey - Chief Financial Officer Todd Nelson - Chief Executive Officer Dan Gibson - Chief Technology Officer Conference Call Participants Paul Knight - KeyBanc Brandon Couillard...
News, Short Squeeze, Breakout and More Instantly...
Codex DNA Inc. Company Name:
DNAY Stock Symbol:
NASDAQ Market:
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...